word count: 245) 16 We manipulated SIVmac239Δnef, a model of MHC-independent viral control, to 17 128 129 Results: 130 131 Construction of SIVΔnef-8x. We engineered a variant of SIVmac239Δnef with point 132 mutations in eight CD8+ T cell epitopes restricted by MHC class I molecules expressed 133 by the M3 haplotype (Figure 1a). All eight epitopes are highly immunogenic and 134 accumulate high frequency escape mutations in response to immunodominant CD8+ T 135 cell responses elicited during infection with either SIVmac239 or SIVmac239Δnef (16, 26, 136 27). For each epitope, we used sequence data from nine M3/M3 MCMs chronically 137 infected with SIVmac239 to identify common variants in the replicating virus population 138
evaluate characteristics of effective cellular responses mounted by Mauritian cynomolgus 18 macaques (MCMs) who express the M3 MHC haplotype that has been associated with 19 poor control of pathogenic SIV. We created SIVΔnef-8x to test the hypothesis that 20 effective SIV-specific T cell responses targeting invariant viral regions can emerge in the 21 absence of immunodominant CD8+ T cell responses targeting variable epitopes, and that 22 control is achievable in individuals lacking known protective MHC alleles. Full proteome 23 2 IFNγ ELISPOT assays identified six newly targeted immunogenic regions following 24 SIVΔnef-8x infection of M3/M3 MCMs. We deep sequenced circulating virus and found 25 that four of the six newly targeted regions rarely accumulated mutations. Six animals 26 infected with SIVΔnef-8x targeted at least one of the four invariant regions and had a 27 lower set point viral load compared to two animals that did not target any invariant regions. 28 We found that MHC class II molecules restricted all four of the invariant peptide regions, 29 while the two variable regions were restricted by MHC class I molecules. Therefore, in 30 the absence of immunodominant CD8+ T cell responses that target variable regions 31 during SIVmac239Δnef infection, individuals without 'protective' MHC alleles developed 32 predominantly CD4+ T cell responses specific for invariant regions that may improve 33 control of virus replication. Our results provide some evidence that antiviral CD4+ T cells 34 during acute SIV infection can contribute to effective viral control and should be 35 considered in strategies to combat HIV infection. Introduction: 54 During HIV infection, virus-specific CD8+ T cell responses are associated with 55 resolution of peak viremia. These responses exert substantial immune pressure that often 56 results in rapid selection for viral escape variants, suggesting that limiting viral escape is 57 beneficial and may prove critical in the design of immunotherapies for HIV (1-4). There is 58 evidence that the control of viremia associated with individuals expressing specific 59 'protective' major histocompatibility complex (MHC) class I alleles may be attributed to 60 CD8+ T cells that target specific peptide epitopes within highly invariant regions where 61 mutations are likely to impart a significant fitness cost (5-8). However, this rare population 62 of 'elite controllers' is estimated at less than 1% of the infected population, while the 63 majority of HIV-infected individuals do not express 'protective' MHC alleles and more 64 frequently mount CD8+ T cell responses that target viral regions that tolerate escape 65 mutations easily (9, 10). Recently, multiple lines of evidence also indicate a nontraditional 66 cytolytic role of HIV-specific CD4+ T cells that cooperate with HIV-specific CD8+ T cells 67 to mediate suppression of virus replication and may be predictive of disease outcome 68 (11) (12) (13) . It is essential for the design of vaccines and therapeutics to determine if virus-69 4 specific CD8+ and/or CD4+ T cell responses can be mounted by individuals not 70 expressing 'protective' MHC alleles, and if these responses are effective at controlling 71 viremia. For an intervention to be truly effective, a universal approach that can contend 72 with the extraordinary sequence diversity of HIV in people with and without 'protective' 73 HLA alleles is needed. 74 Using nonhuman primates, we can determine if acute-phase T cell responses 75 targeting invariant viral regions can control primary viremia. Similar to humans, some 76 macaques express 'protective' MHC class I alleles associated with control of SIV 77 replication (14-16). However, these studies have yet to define why control of virus 78 replication in individuals expressing 'protective' MHC alleles is incompletely penetrant, 79 and they do not address how to induce viral control in animals without 'protective' MHC 80 alleles (17). Far less is known about the specificity of SIV-specific CD4+ T cell responses 81 and whether they may also directly suppress virus replication. Only recently, has there 82 been interest in developing immunogens to elicit antiviral T cells targeting conserved viral 83 regions across individuals with diverse MHC alleles, in vivo (18-20). Mauritian 84 cynomolgus macaques (MCMs) are ideal for studying pathogen-specific T cells because 85 they have extremely restricted MHC class I and II genetics, such that nearly all of their 86 MHC alleles can be explained by 7 common haplotypes, termed M1-M7 (21). As a result, 87 MHC-identical animals with the potential to present identical T cell peptide epitopes can 88 be selected for studies (21, 22 (data not shown). We then used either these identified variant peptide sequences or the 143 variant peptide sequences we included in m3KOΔnef into SIVmac239Δnef (25). We 144 referred to the resulting virus as SIVΔnef-8x to denote its origin as an SIVmac239Δnef 145 derivative with point mutations aimed at disrupting the immunogenicity of the eight 146 variable M3-restricted CD8+ T cell epitopes present in SIVmac239Δnef (Figure 1a ). 147 To test if the epitope variants incorporated into SIVΔnef-8x affected viral fitness, 148 we performed in vitro co-culture competition assays with a barcoded SIVmac239Δnef 149 (BCVΔnef) containing 10 synonymous changes in gag that can be detected by a separate Figure 3a ). The limit of detection for the viral load assay 186 was 100 copies/mL. We did not observe peak viral load to be significantly different Figure 3d ). We modeled this with Kaplan-Meier survival curves 208 using a threshold for control similar to that of 'elite controller' macaques infected with 209 SIVmac239 (<1,000 vRNA copies/mL)(14) (15). Similar to comparisons of set point viral 210 load, we did not find significant differences in time to establish control of virus replication 211 between the three cohorts. week 3) and post-peak (week 7-9) infection, we identified six immunogenic regions in the 220 SIVΔnef-8x proteome that elicited T cell responses to peptide sequences in Gag (n=5) 221 and Env (n=1) that were not previously characterized in SIV-infected M3/M3 MCMs. of these new regions during acute or post-peak infection in the two animals (cy0690 and 228 cy0755) that did not control SIVΔnef-8x replication. 229 We deep sequenced viral populations in parallel to determine if these six newly SIVmac239 (43), we found the V63A mutation was present in virus populations from both 299 controllers and non-controllers of SIVΔnef-8x (data not shown). Our results suggest that 300 this mutation, alone, does not confer breakthrough replication, so perhaps targeting this 301 region of Gag may still offer some immunological benefit. 302 We also observed high-frequency mutations in Env329-349VG19; a region that is 303 located at the C-terminus of the V3 loop (44) . This region also contains the variant epitope There is growing evidence that HIV-specific CD4+ T cells may play a bigger 318 cytolytic role in control of virus replication than previously thought (11, 37, 47, 48) . SIV-319 specific CD4+ responses have been previously detected in macaques infected with 320 pathogenic SIV (49, 50). While observed to be typically subdominant in comparison to 321 many CD8+ T cell responses, immune pressure imparted by CD4+ T cells has been 322 sufficient to select for escape variants in certain cases (28, 43, 51). We found four 323 immunogenic regions that elicited acute phase CD4+ T cells in M3/M3 animals infected 324 with SIVΔnef-8x. All four of these were located in Gag and did not accumulate mutations (11, 47, 52) . This 331 argument lies in contrast to virus-specific CD4+ T cells as preferential targets of infection, 332 and may be explained by distinct transcriptional and functional signatures of cytolytic 333 CD4+ T cells that mirror CD8+ T cells more than Th1 CD4+ cells (13, 53, 54). Together, 334 we provide evidence that acute phase CD4+ T cells may improve control of SIV 335 replication, and we provide a model in which to further explore this mechanism in future 336 studies. 337 We did find that two M3/M3 MCMs infected with SIVΔnef-8x (cy0690 and cy0755) Plasma viral load analysis. Plasma was isolated from whole blood by ficoll-based 401 density centrifugation and cryopreserved at -80°C. SIV gag loads were determined as 402 previously described (34). Briefly, vRNA was isolated from plasma, reverse transcribed, 403 and amplified with the Superscript III Platinum one-step quantitative reverse transcription-404 PCR (qRT-PCR) system (Invitrogen). The detection limit of the assay was 100 vRNA copy 405 equivalents per mL of plasma (copies/mL). The limit of detection value (100 copies/mL) 406 was reported when the viral load was at or below the limit of detection. 
